Iovance Biotherapeutics

Yahoo Finance • 10 days ago

Iovance Biotherapeutics to Present at Upcoming Conference

SAN CARLOS, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies f... Full story

Yahoo Finance • last month

Is Viking Therapeutics, Inc. (VKTX) A Good Stock To Buy Now?

Is VKTX a good stock to buy? We came across a bullish thesis on Viking Therapeutics, Inc. on Charlie Evans’s Substack by Charlie Evans PhD. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.'s share was... Full story

Yahoo Finance • last month

Iovance Biotherapeutics Inc (IOVA): Jefferies Draws Attention Amtagvi Drug

Iovance Biotherapeutics Inc (NASDAQ:IOVA) is among the must-buy penny stocks to invest in now. The stock has climbed more than 66% over the past six months and currently trades at around $3.86. On April 10, Jefferies reaffirmed a Buy ratin... Full story

Yahoo Finance • last month

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrati... Full story

Yahoo Finance • 2 months ago

Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster

Neurocrine Biosciences logo 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking Neurocrine Biosciences (NASDAQ:NBIX) detailed its planned acquisition of Soleno Therapeutics on a conference call Monday, outlining the deal terms, the s... Full story

Yahoo Finance • 3 months ago

Tempus AI, Inc. (TEM) Announces Strategic Deal with Merck to Fast-Track AI-Driven Precision Medicine

Tempus AI, Inc. (NASDAQ:TEM) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026. On March 3, the company announced a strategic partnership with Merck to fast-track the development of AI-driven precision medicine and suppo... Full story

Yahoo Finance • 3 months ago

UBS Raises PT on Iovance Biotherapeutics (IOVA)

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the Low Risk Penny Stocks to Buy Now. On March 5, UBS analyst David Dai raised the firm’s price target on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) from $2 to $4, while maintaining a... Full story

Yahoo Finance • 3 months ago

Iovance Biotherapeutics GAAP EPS of -$0.18 in-line, revenue of $86.71M beats by $5.7M

* Iovance Biotherapeutics press release [https://seekingalpha.com/pr/20410351-iovance-biotherapeutics-highlights-strong-fourth-quarter-and-full-year-2025-results-business] (IOVA [https://seekingalpha.com/symbol/IOVA]): Q4 GAAP EPS of -$0... Full story

Yahoo Finance • 3 months ago

Is Iovance Biotherapeutics Inc. (IOVA) One of the Best Immunotherapy Stocks to Buy According to Hedge Funds?

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best immunotherapy stocks to buy according to hedge funds. On February 5, Goldman Sachs lifted the price target on Iovance Biotherapeutics Inc. (NASDAQ:IOVA) to $2 from $1.50 while m... Full story

Yahoo Finance • 4 months ago

Iovance Biotherapeutics (IOVA) Gives Update on Revenue Guidance, Lung Cancer Cure

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best stocks under $3 to invest in. On January 9, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) announced that it expects to achieve its previously disclosed full-year 2025 revenue guida... Full story

Yahoo Finance • 4 months ago

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL)... Full story

Yahoo Finance • 5 months ago

Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best biotech penny stocks to buy according to analysts. On December 17, Barclays analyst Etzer Darout raised the firm’s price target on Iovance Biotherapeutics to $10 from $9, while... Full story

Yahoo Finance • 5 months ago

2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street

Key Points A clinical hold and a complex commercial path make Intellia Therapeutics' outlook uncertain. Despite steadily growing revenue, Iovance Biotherapeutics faces nearly insurmountable challenges. 10 stocks we like better than Intell... Full story

Yahoo Finance • 7 months ago

Iovance Biotherapeutics reports mixed Q3 results; reaffirms FY25 outlook

* Iovance Biotherapeutics press release [https://seekingalpha.com/pr/20296680-iovance-biotherapeutics-highlights-business-achievements-pipeline-milestones-and-third] (IOVA [https://seekingalpha.com/symbol/IOVA]): Q3 GAAP EPS of -$0.25 be... Full story

Yahoo Finance • 7 months ago

IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance (IOVA) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Iovance between May 9, 2024 an... Full story

Yahoo Finance • 8 months ago

Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire?

Key Points Iovance Biotherapeutics was the first drug developer to win FDA approval of an immune cell/T-cell therapy. The underlying science, however, may offer more long-term potential than the single drug in question. This stock’s treme... Full story

Yahoo Finance • 8 months ago

IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance (IOVA) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Iovance between May 9, 2024 an... Full story

Yahoo Finance • 8 months ago

Shares of WOR Now Oversold

In trading on Wednesday, shares of Worthington Enterprises Inc (Symbol: WOR) entered into oversold territory, changing hands as low as $50.55 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a te... Full story

Yahoo Finance • 8 months ago

Can This Beaten-Down Stock Bounce Back?

Key Points Iovance Biotherapeutics' cancer therapy, Amtagvi, is experiencing decent sales growth. However, the biotech faces some challenges that will make it difficult to turn a profit. Though there could be some catalysts on the way, Io... Full story

Yahoo Finance • 8 months ago

Advancing Cancer Research Brings New Hope for Patients Worldwide

NetworkNewsWire Editorial Coverage NEW YORK, Sept. 17, 2025 /PRNewswire/ -- Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma... Full story